Actively Recruiting
AlloMend Acellular Dermal Matrix Allograft in Pre-Pectoral Breast Reconstruction
Led by AlloSource · Updated on 2025-11-21
200
Participants Needed
1
Research Sites
167 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single-center, retrospective study which will be used to describe and evaluate the effectiveness of AlloMend® Acellular Dermal Matrix allograft for patients that have undergone Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.
CONDITIONS
Official Title
AlloMend Acellular Dermal Matrix Allograft in Pre-Pectoral Breast Reconstruction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients 18 years of age or older
- Diagnosed by a physician and required a single or double mastectomy followed by pre-pectoral breast reconstruction surgery using AlloMend4 Acellular Dermal Matrix allograft
- Surgical intervention included the use of AlloMend4 Acellular Dermal Matrix allograft
- Completed or will complete clinical follow-up visits at 2 weeks, 6 weeks, 3 months, and 6 months after surgery
You will not qualify if you...
- Did not use AlloMend4 Acellular Dermal Matrix allograft during pre-pectoral breast reconstruction
- Did not have post-operative evaluations at the clinical site
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Alan H. Chen Surgical Associates, PC
Joliet, Illinois, United States, 60435
Actively Recruiting
Research Team
E
Elizabeth Esterl, DNP, MS, RN
CONTACT
P
Paige McHenry, MS, ATC, CCRA
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here